Physicochemical interaction of antitumor acridinone derivatives with DNA in view of QSAR studies

Medicinal Chemistry Research

Volumn 20, Issue 8, 2011, Pages 1385-1393

  Koba, Marcin ^a   Bączek, Tomasz ^b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Acridinones; Antitumor activity; Multiple linear regression (MLR) analysis; Physicochemical interaction with DNA; Quantitative structure activity relationships (QSAR)

Indexed keywords

ACRIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; DOUBLE STRANDED DNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPUTER PROGRAM; DRUG DNA BINDING; DRUG MECHANISM; HYDROPHOBICITY; MOUSE; NONHUMAN; PHYSICOCHEMICAL MODEL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 80054720188     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9487-y     Document Type: Article

References (40)

1. Alami N, Paterson J, Belanger S, Juste S, Grieshaber CK, Leyland- Jones B (2007) Comparative cytotoxicity of C-1311 in colon cancer in vitro and in vivo using the hollow fiber assay. J Chemother 19:546-553 (Pubitemid 350177966)
2. Augustin E, Plocka E, Konopa J (2004) Induction of cell death (apoptosis) by antitumor triazoloacridinones in tumor cells. Drug Metab Rev 32(suppl. 1):33
3. Augustin E, Mos-Rompa A, Skwarska A, Witkowski JM, Konopa J (2006) Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305. Biochem Pharmacol 72:1668-1679 (Pubitemid 44765001)
4. Berger B, Marguardt H, Westendorf J (1996) Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res 56:2094-2104 (Pubitemid 26120600)
5. Bram EE, Ifergan I, Grimberg M, Lemke K, Skladanowski A, Assaraf YG (2007) C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells. Biochem Pharmacol 74:41-53 (Pubitemid 46802491)
6. Burger AM, Double JA, Konopa J, Bibby MC (1996) Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer 74:1369-1374 (Pubitemid 26370726)
7. Burger AM, Jenkins TC, Double JA, Bibby MC (1999) Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 81:367-375 (Pubitemid 29423720)
8. Calabrese CR, Bibby MC, Double JA, Loadman PM (1998) Pharmacokinetics and tissue distribution of the imidazoacridinone C1311 in tumour-bearing mice. Cancer Chemother Pharmacol 42:379-385 (Pubitemid 28430368)
9. Calabrese CR, Loadman PM, Lim LS, Bibby MC, Double JA, Brown JE, Lamb JH (1999) In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans. Drug Metab Dispos 27:240-245 (Pubitemid 29072078)
10. Cholody WM, Martelli S, Konopa J (1990) 8-substituted 5-[(aminoalkyl) amino]-6H-v-triazolo[4,5,1-de]acridin-6-ones as potential antineoplastic agents. J Med Chem 33:2852-2856 (Pubitemid 20312155)
11. Cholody WM, Martelli S, Konopa J (1992) Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. J Med Chem 35:378-382
12. Cholody WM, Horowska B, Paradziej-Lukowicz J, Martelli S, Konopa J (1996) Structure-activity relationship for antineoplastic imidazoacridinones: Synthesis and antileukemic activity against murine leukemias. J Med Chem 39:1028-1032 (Pubitemid 26082935)
13. De Marco C, Zaffaroni N, Comijn E, Tesei A, Zoli W, Peters GJ (2007) Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in a panel of human solid tumour and leukaemia cell lines. Int J Oncol 31:907-913
14. Den Brok MW, Nuijen B, Harms R, Buluran JN, Harvey MD, Grieshaber CK, Beijnen JH (2005a) Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility. J Oncol Pharm Pract 11:13-19 (Pubitemid 40674353)
15. Den Brok MW, Nuijen B, Hillebrand MJ, Grieshaber CK, Harvey MD, Beijnen JH (2005b) Development and validation of an LCUV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form. J Pharm Biomed Anal 39:46-53 (Pubitemid 41112118)
16. Den Brok MW, Nuijen B, Kettenes-Van Den Bosch JJ, Van Steenbergen MJ, Buluran JN, Harvey MD, Grieshaber CK, Beijnen JH (2005c) Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311. PDA J Pharm Sci Technol 59:285-297 (Pubitemid 41611872)
17. Dziegielewski J, Konopa J (1996) Interstrand crosslinking of DNA induced in tumor cells by a new group of antitumor imidazoacridinones. Proc Am Assoc Cancer Res 37:410
18. Dziegielewski J, Slusarski B, Konitz A, Skladanowski A, Konopa J (2002) Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol 63:1653-1662 (Pubitemid 34458004)
19. Hyzy M, Bozko P, Konopa J, Skladanowski A (2005) Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochem Pharmacol 69:801-809 (Pubitemid 40248622)
20. Ivanciuc O (1996) HyperChem release 4.5 for Windows. Inf Comput Sci 36:612-614
21. Kaliszan R, Turowski M, Buciński A, Hartwick RA (1995) Quantitative structure-retention relationships in capillary electrophoresis of inorganic cations and b-adrenolytic and sulfonamided compomids. Quant Struct Act Relat 14:356-361
22. Koba M, Konopa J (2007) Interactions of antitumor triazoloacridinones with DNA. Acta Biochim Pol 54:297-306 (Pubitemid 47057873)
23. Koba M, Koba K, Bačzek T (2009) Is DNA minor groove binding crucial for biological activity of triazoloacridinones with cytotoxic and antitumour properties? Lett Drug Des Discov 6:242-245
24. Kusnierczyk H, Cholody WM, Paradziej-Lukowicz J, Radzikowski C, Konopa J (1994) Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immunol Ther Exp 42:414-423
25. Lamb J, Wheatley DN (1996) Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation. Br J Cancer 74:1359-1368 (Pubitemid 26370725)
26. Lemke K, Poindessous V, Skladanowski A, Larsen AK (2004) The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Mol Pharmacol 66:1035-1042 (Pubitemid 39319476)
27. Lemke K, Wojciechowski M, Laine W, Bailly C, Colson P, Baginski M, Larsen AK, Skladanowski A (2005) Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities. Nucleic Acids Res 33:6034-6047 (Pubitemid 41742622)
28. Mazerska Z, Augustin E, Dziegielewski J, Cholody MW, Konopa J (1996) QSAR of acridines, III. Structure-activity relationship for antitumour imidazoacridinones and intercorrelations between in vivo and in vitro tests. Anticancer Drug Des 11:73-88 (Pubitemid 26084440)
29. Mazerska Z, Augustin E, Skladanowski A, Bibby MC, Double JA, Konopa J (1998) C-1311. Drugs Future 23:702-706
30. Mazerska Z, Gorlewska K, Kraciuk A, Konopa J (1999) The relevance of enzymatic oxidation by horseradish peroxidase to antitumour potency of imidazoacridinone derivatives. Chem Biol Interact 115:1-22
31. Mazerska Z, Sowiński P, Konopa J (2003) Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311. Biochem Pharmacol 66:1727-1736 (Pubitemid 37249317)
32. Mazerski J, Muchniewicz K (2000) The intercalation of imidazoacridinones into DNA induces conformational changes in their side chain. Acta Biochim Pol 47:65-78
33. Put R, Daszykowski M, Bačzek T, Vander Heyden Y (2006) Retention prediction of peptides based on uninformative variable elimination by partial least squares. J Proteome Res 5:1618-1625 (Pubitemid 44036136)
34. Skladanowski A, Konopa J (2000) Mitoxantrone and ametantrone induce interstrand cross-links in DNA of tumour cells. Br J Cancer 82:1300-1304 (Pubitemid 30145349)
35. Skladanowski A, Plisov SY, Konopa J, Larsen AK (1996) Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumor. Mol Pharmacol 49:772-780 (Pubitemid 26149906)
36. Skladanowski A, Larsen AK, Konopa J, Lemke K (1999) Inhibition of DNA topoisomerase II by antitumor triazoloacridinones in vitro and in tumor cells. Proc Am Assoc Cancer Res 40:681
37. Skwarska A, Augustin E, Konopa J (2007) Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311. Apoptosis 12: 2245-2257 (Pubitemid 350077255)
38. Todeschini R, Consonni V, Mannhold R, Kubinyi H, Timmerman H (2000)Handbook of molecular descriptors.Wiley-VCH,Weinheim
39. Wesierska-Gadek J, Schloffer D, Gueorguieva M, Uhl M, Skladanowski A (2004) Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest. Cancer Res 64:4487-4497 (Pubitemid 38856920)
40. Zaffaroni N, De Marco C, Villa R, Riboldi S, Daidone MG, Double JA (2001) Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. Eur J Cancer 37:1953-1962 (Pubitemid 32913325)